Metis Global Partners LLC Sells 244 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Metis Global Partners LLC reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,226 shares of the biopharmaceutical company’s stock after selling 244 shares during the quarter. Metis Global Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $4,590,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Raymond James Financial Services Advisors Inc. grew its holdings in Regeneron Pharmaceuticals by 0.5% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 8,391 shares of the biopharmaceutical company’s stock worth $6,905,000 after acquiring an additional 42 shares during the last quarter. Stratos Wealth Partners LTD. increased its stake in shares of Regeneron Pharmaceuticals by 29.4% in the third quarter. Stratos Wealth Partners LTD. now owns 466 shares of the biopharmaceutical company’s stock valued at $383,000 after buying an additional 106 shares during the period. Everhart Financial Group Inc. raised its position in shares of Regeneron Pharmaceuticals by 13.1% during the third quarter. Everhart Financial Group Inc. now owns 388 shares of the biopharmaceutical company’s stock worth $319,000 after acquiring an additional 45 shares during the last quarter. Lindbrook Capital LLC boosted its holdings in Regeneron Pharmaceuticals by 3.7% in the third quarter. Lindbrook Capital LLC now owns 1,030 shares of the biopharmaceutical company’s stock valued at $848,000 after acquiring an additional 37 shares during the last quarter. Finally, GPS Wealth Strategies Group LLC lifted its position in shares of Regeneron Pharmaceuticals by 8.6% in the 3rd quarter. GPS Wealth Strategies Group LLC now owns 443 shares of the biopharmaceutical company’s stock worth $365,000 after purchasing an additional 35 shares during the period. Institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

REGN has been the topic of a number of recent analyst reports. Barclays boosted their price objective on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a research note on Tuesday, January 23rd. BMO Capital Markets increased their target price on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a report on Monday, February 5th. Morgan Stanley boosted their price objective on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 13th. Sanford C. Bernstein began coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 price objective for the company. Finally, TD Cowen boosted their price objective on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $981.71.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Joseph J. Larosa sold 1,000 shares of the stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $950.00, for a total value of $950,000.00. Following the completion of the sale, the executive vice president now owns 38,543 shares in the company, valued at approximately $36,615,850. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Regeneron Pharmaceuticals news, EVP Joseph J. Larosa sold 1,000 shares of the stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $950.00, for a total transaction of $950,000.00. Following the completion of the transaction, the executive vice president now owns 38,543 shares in the company, valued at $36,615,850. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $982.05, for a total value of $98,205.00. Following the completion of the transaction, the director now owns 18,282 shares of the company’s stock, valued at approximately $17,953,838.10. The disclosure for this sale can be found here. Insiders have sold 9,095 shares of company stock valued at $8,729,766 over the last 90 days. 8.83% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN traded up $1.64 during midday trading on Monday, hitting $958.64. 344,072 shares of the company’s stock traded hands, compared to its average volume of 498,127. The firm has a fifty day moving average of $943.75 and a 200 day moving average of $897.24. Regeneron Pharmaceuticals, Inc. has a 1 year low of $684.80 and a 1 year high of $998.33. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. The stock has a market capitalization of $105.22 billion, a price-to-earnings ratio of 28.27, a price-to-earnings-growth ratio of 2.74 and a beta of 0.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, topping the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The firm had revenue of $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. During the same period in the prior year, the business posted $10.96 EPS. Regeneron Pharmaceuticals’s revenue was up .6% on a year-over-year basis. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.86 earnings per share for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.